ABSTRACT
Protein kinase A (PKA), a signal-transducing protein playing a key role in the control of cell growth and differentiation, is present in mammalian cells in two distinct isoforms, type I (PKAI) and type II (PKAII) (1, 2) . PKAI is directly involved in cell proliferation and neoplastic transformation (1, 3) , is required for the G 1 Ͼ S transition of the cell cycle (3), mediates the mitogenic signals of different growth factors including epidermal growth factor and transforming growth factor type ␣ (4-6), and is overexpressed in the majority of human cancers, correlating with worse clinicopathological features and prognosis in ovarian and breast cancer patients (7, 8) . Conversely, PKAII is preferentially expressed in normal tissues and seems to be involved in cell growth arrest and differentiation (1, 9, 10) . It has been shown that the selective down-regulation of PKAI by the site-selective cAMP analog 8-Cl-cAMP leads to inhibition of cancer cell growth in a wide variety of cancer cell types in vitro and in vivo (1, 4, 5, 11, 12) and is accompanied by inhibition of expression of different oncogenes and growth factors (1, 4, 5, 11) . Several studies have also demonstrated that different antisense oligodeoxynucleotides targeting the RI␣ subunit of PKAI expression cause cell growth arrest and differentiation in a wide variety of cancer cell lines (13, 14) . A recent study has shown that an RI␣ antisense phosphorothioate oligodeoxynucleotide (PS-oligo) is able to inhibit the growth of human colon cancer xenografts in nude mice (15) .
A large number of in vitro and in vivo studies have demonstrated that PS-oligos complementary to the mRNA of proteins involved in the process of neoplastic transformation and progression are effective in inhibiting cancer cell growth (15) (16) (17) (18) (19) (20) (21) . However, toxicity studies conducted with PS-oligos in animal models and humans have shown dose-dependent side effects, which may be due to the polyanionic structure of PS-oligos and to mitogenic immune response (22) (23) (24) . Presently, PS-oligos are being tested for their therapeutic potential in human clinical trials. Although PS-oligos have shown promising results as the first generation of oligonucleotides, to further improve their therapeutic potential we have studied mixed-backbone oligonucleotides (MBOs). MBOs have appropriately placed segments of PS-oligo and segments of modified oligodeoxy-or oligoribonucleotides (24) . The MBO that we have used in the present study contains five methylphosphonate linkages in the middle of the PS-oligo. These centrally modified oligonucleotides have shown a significant reduction of side-effects in vivo compared with PS-oligos (24) .
We have used a MBO targeting the RI␣ subunit of PKAI, alone or in combination with a series of cytotoxic drugs, to determine its antiproliferative effect in vitro and in vivo on a variety of human cancer cell lines. We have demonstrated that the RI␣ antisense MBO inhibits the growth of different human cancer cell lines at submicromolar concentrations and has a synergistic growth inhibitory activity with various classes of cytotoxic drugs, including taxanes, platinum-derived agents, and topoisomerase II-selective drugs. Finally, we have observed in absence of toxicity a cooperative antitumor effect of the antisense with paclitaxel in nude mice.
OVCAR-3 human ovarian cancer cells were purchased from American Type Culture Collection. Docetaxel was a kind gift of Rhone-Poulenc Rorer (Antony Cedex, France). 5-Fluorouracil, methotrexate, cisplatin, camptothecin, doxorubicin, etoposide, paclitaxel, carboplatin, and vincristine were purchased from Sigma. All drugs were diluted in appropriate solvents and used as ϫ100 concentrated stock.
MBOs. Cell Growth Experiments and Antisense Treatment. LS 174T, MDA-MB-231, and MDA-MB-468 cell lines were maintained in DMEM. OVCAR-3 cells were grown in a 1:1 mixture of DMEM and Ham's-F12 medium. GEO cells were grown in McCoy medium. All media, purchased from Flow Laboratories, were supplemented with 10% heat inactivated fetal bovine serum͞20 mM Hepes, pH 7.4͞5 mM glutamine͞100 units ml penicillin͞100 g͞ml streptomycin (Flow Laboratories). Cells were maintained in a humidified atmosphere of 95% air͞5% CO 2 at 37°C. For cell growth experiments in soft agar 10 4 cells͞well were seeded in 24 multiwell cluster dishes as described (4) and treated with different concentrations of the indicated cytotoxic drug (day 0). The HYB 190 or HYB 239 antisense RI␣ MBO were added after 12 h (day 1) and on days 2, 3, and 4. Twelve days after the last treatment, cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.
Flow Cytometric Analysis of Cell Cycle by Propidium Iodide Staining. Cells seeded in monolayer in 6-well dish clusters were treated with the indicated cytotoxic drug. After 24 hrs (day 1) either HYB 190 or HYB 239 antisense RI␣ was added and the treatment was repeated on days 2, 3, and 4. At the indicated time points cells were harvested, fixed in 70% ethanol, stained with a propidium iodide solution (Sigma), and their DNA content was analyzed in duplicate by a FACScan flow-cytometer (Becton Dickinson) coupled with a HewlettPackard computer, as described (4) . Cell cycle data analysis was performed by the CELL-FIT program (Becton Dickinson) (4).
Apoptosis. Flow cytometric analysis of apoptotic cell death was performed on cell pellet fixed in ethanol 70%, washed in PBS, and mixed with RNase (Sigma) and propidium iodide solution following the method reported (25) . DNA content was analyzed by a FACScan flow-cytometer (Becton Dickinson) coupled with a Hewlett-Packard computer, and the percent of apoptotic cells was calculated using the LYSYS software (Becton Dickinson).
In Vivo Studies with Antisense in Nude Mice. Five-to 6-week-old female BALB͞c athymic (nu ϩ ͞nu ϩ ) mice were purchased from Charles River Breeding Laboratories. The research protocol was approved and mice were maintained in accordance to institutional guidelines of the University of Naples Animal Care and Use Committee. Mice were acclimated to the University of Naples Medical School Animal Facility for 1 week prior to being injected with cancer cells. Mice were injected s.c. with 10 7 GEO cells that had been resuspended in 200 l of Matrigel (Collaborative Biomedical Products, Bedford, MA). After 10 days, when well established tumors of approximately 0.4 cm 3 in diameter were detected, seven mice͞group were treated i.p. either with paclitaxel (20 mg͞kg) (26) (once, on day 1), or with the MBOs HYB 190 (10 mg͞kg) or HYB 239 (10 mg͞kg) (for 5 days, from day 2 to 6), or with paclitaxel in combination with either HYB 190 or HYB 239 in a sequential schedule; that is, the mice received the cytotoxic drug first (day 1), then, the oligonucleotides were administered for 5 consecutive days (day 2-6). Tumor size was measured twice weekly up to 67 days from tumor cell injection. Tumor size was measured using the formula ͞6 ϫ larger diameter ϫ (smaller diameter) 2 , as reported (27) .
Statistical Analysis. The Student's t test (28) was used to evaluate the statistical significance of the results. All P values represent two-sided tests of statistical significance. All analyses were performed with the BMDP NEW SYSTEM statistical package version 1.0 for Microsoft Windows (BMDP Statistical Software, Los Angeles). (Fig. 1A) , the control MBO HYB 239 at the same doses showed a modest or no growth inhibitory effect (Fig. 1B) . Western blot analysis after treatment with the antisense RI␣ MBO in OVCAR-3 ovarian and GEO colon cancer cells confirmed a dose-dependent inhibition of RI␣ expression in HYB 190-but not in HYB 239-treated cells (data not shown).
RESULTS

Effect
Effects of RI␣ Antisense MBO in Combination with Cytotoxic Drugs. HYB 190 at a dose of 0.1 M showed an inhibition of OVCAR-3 ovarian cancer cell growth of approximately 15% (Fig. 1 A) , whereas HYB 239 at the same concentration caused less than 10% inhibition (Fig. 1B) . Therefore, we selected this low dose to study whether any cooperative -0.1 ng͞ml) , which, when used as single agent, showed a growth inhibition between 20% and 60%, an additive growth inhibitory effect was observed on soft agar colony formation (data not shown). A marked synergistic effect was observed when HYB 190 was added to OVCAR-3 treated with paclitaxel, cisplatin, doxorubicin, or etoposide ( Fig. 2 A and C) . Conversely, HYB 239 at doses ranging between 0.1 and 1 M had no such effect when combined with the same cytotoxic agents (Fig. 2 B and D) . The cooperative antiproliferative effect was not restricted to ovarian cancer cells. In fact, when 0.01 M HYB 190 , which caused 22% growth inhibition in GEO colon cancer, or at 0.1 M, which inhibits 5% of the growth of MDA-MB-231 breast cancer cells, were added to paclitaxel, cisplatin, or doxorubicin, a synergistic growth inhibitory effect was observed. For example, in GEO cells, treatment with 0.01 M HYB 190 in combination with 1 nM paclitaxel, 0.05 g͞ml cisplatin, or 0.05 g͞ml doxorubicin, which used alone showed 7%, 2%, and 25% growth inhibition, respectively, caused a 60%, 62%, and 78% inhibition of colony formation, respectively.
To study whether this cooperative effect occurs also with other drugs of the same classes, we tested the effect of HYB190 when added to OVCAR-3 cells treated with either the taxane docetaxel or the platinum derivative carboplatin. With each drug, HYB 190 caused a synergistic inhibition of growth. In fact, in cells treated with 0.5 or 1 nM docetaxel, which alone cause 20% and 45% growth inhibition, respectively, addition of 0.1 M HYB 190 caused a growth inhibition of 60% and 85%, respectively. An even more dramatic effect was obtained with carboplatin, where the mild growth inhibitory effect produced by this drug at 0.5 g͞ml (6%) or 1 g͞ml (11%) increased to 70% and 90%, respectively, after the addition of 0.1 M HYB 190 to OVCAR-3 cells.
Cell Cycle Analysis and Evaluation of Apoptosis. We have analyzed the effect of the treatment with the MBOs and͞or the cytotoxic drugs on the cell cycle distribution of the cancer cells. In the same cell population, we conducted a time-dependent analysis of apoptosis by f lowcytometry (Fig. 3) . Although apoptosis was present only in 6-9% of untreated cells, a marked percent of apoptotic cells (46%) was present after 4 days of treatment with 0.1 M HYB 190 alone and remained over 20% in the cell population examined at 8 and 12 days after treatment. Paclitaxel (1 nM) showed a high percent (about 40% or more) of apoptotic cell death throughout the time course, whereas treatment with both agents in combination always showed, at all time points examined, a percent of apoptosis higher than that obtained with each agent alone.
Effect of RI␣ Antisense in Nude Mice. To evaluate whether the cooperative effect observed in vitro could be obtained also in vivo, we used nude mice bearing GEO cell xenografts (27) . When large GEO tumors of approximately 0.4 cm 3 were detected, seven mice͞group were treated i.p. with paclitaxel (20 mg͞kg, the maximum tolerated dose in mice) (26) , HYB 190 (10 mg͞kg͞dose), and HYB 239 (10 mg͞kg͞dose) used as single agent, or with paclitaxel in combination with either HYB 190 or HYB 239 in a sequential schedule (Fig. 4) . As compared with untreated animals, a significant delay of tumor growth was observed in mice either treated with paclitaxel (two-sided P ϭ 0.05) or with antisense HYB 190 (two-sided P ϭ 0.05), whereas the control oligomer HYB 239 exhibited only a mild growth inhibitory effect. A marked tumor growth inhibition was obtained in mice treated with paclitaxel plus HYB 190, which was statistically significant as compared with control untreated mice (two-sided P ϭ 0.01), or mice treated with either paclitaxel (two-sided P ϭ 0.04) or HYB 190 (two-sided P ϭ 0.01) alone. In contrast, in mice treated with paclitaxel plus the control oligomer HYB 239 the tumor growth inhibition was similar to that determined by the cytotoxic drug alone. Moreover, tumors grew to a size not compatible with normal life in all untreated mice or in those treated with HYB 239 within 40 days after tumor cell injection, and in all mice treated with either paclitaxel, HYB 190 alone, or paclitaxel plus HYB 239 within 60 days. In contrast, all mice treated with the sequential combination of paclitaxel and antisense RI␣ HYB 190 were still alive and tumor growth was still very slow up to 67 days after GEO cell injection. Finally, no weight loss or other signs of acute or delayed toxicity were observed in this group of mice.
DISCUSSION
Emerging novel strategies of cancer treatment are based on the selective down-regulation of specific targets involved in the process of neoplastic transformation and progression. PKAI seems to be a relevant target for such therapeutic intervention, and antisense oligonucleotides against its RI␣ subunit have shown promising results in inhibiting cancer cell growth in vitro and in vivo (13) (14) (15) . In the present study, we have used a second generation modified oligonucleotide with mixed backbone structure (18, 24) We have demonstrated that HYB 190 is additive when added to cells treated with the antimetabolites fluorouracil or methotrexate, the vinca alcaloid vincristine, or the topoisomerase I-selective drug camptothecin. A marked synergistic effect was observed when HYB 190 was used in combination with the taxanes paclitaxel and docetaxel, the platinum derivatives cisplatin and carboplatin, and the topoisomerase II-selective agents doxorubicin and etoposide. In contrast, no cooperative effect was obtained when the same drugs were added to the same or higher doses of control MBO HYB 239. It is likely that the inhibition of the PKAI-related mitogenic pathway plays a key role in the observed cooperative effect with the cytotoxic drugs. In fact, we have recently shown that 8-Cl-cAMP, another selective inhibitor of PKAI expression, has a synergistic growth inhibitory effect with taxanes and platinumderived compounds in a variety of cancer cell types (29, 30) .
In the attempt to understand the kinetics of these events, we analyzed the effect on cell cycle and apoptosis of the antisense compounds with or without the cytotoxic drugs. Whereas paclitaxel causes accumulation of cells in G 2 -M phases, the antisense HYB 190 tends to first accumulate cells in G 0 ͞G 1 and, later, in S͞G 2 -M phase. These results are consistent with our previous report that PKAI is important in the G 1 -S transition (3) and with our most recent observation that PKAI, together with the surge at the G 1 -S transition, has a second peak of expression at the late S͞early G 2 phase (31) . Along with these cell cycle perturbations, apoptosis seems to be present very early after treatment with either RI␣ antisense or the cytotoxic drug alone. When the antisense MBO is administered in combination with the cytotoxic drug in the sequen- tial treatment, a marked increase in the S-G 2 phase is observed throughout the course of the experiment. Interestingly, a consistent amount of apoptotic cells, over 50%, is present for several days after treatment, suggesting that cells undergo several rounds of apoptosis. These data seem in agreement with a recent study suggesting that uncoupling between increase of S phase and inhibition of cell division is a major event occurring after treatment with certain cytotoxic drugs inducing apoptosis (32) .
We next evaluated whether the cooperative effect obtained in vitro could also be reproduced in vivo in nude mice bearing GEO human colon cancer xenografts. We have shown that, unlike the control oligo HYB 239, which only mildly inhibited GEO tumor growth, HYB 190 significantly delayed tumor growth as compared with control mice. Moreover, whereas HYB 239 combined with paclitaxel had an effect similar to that of paclitaxel alone, combination of paclitaxel with HYB 190 determined a significantly increased tumor growth inhibition as compared with untreated mice or to mice treated with each single agent. In addition, all control mice or mice treated with HYB 239 died within 40 days whereas mice treated with HYB 190 alone, paclitaxel alone, or paclitaxel in combination with HYB 239 died within 60 days. In contrast, at the same time point, all animals treated with paclitaxel and HYB 190 (i) showed over 50% tumor growth inhibition as compared with mice treated with either agent alone, (ii) were alive at 67 days, and (iii) the tumor growth was still very slow although the combination treatment was completed 15 days after tumor cell injection. Remarkably, HYB 190 significantly increased the activity of paclitaxel but not the toxicity, considering that the taxane was used at the maximum tolerated dose in nude mice (26) .
Our study reports that a relevant cooperative effect toward tumor growth inhibition can be achieved in vitro and in vivo by combining specific cytotoxic drugs with second generation oligodeoxynucleotides targeting PKAI. Moreover, we have provided evidence that the inhibitory effect correlates with a marked induction of apoptosis and does not result in increased toxicity. Experiments are ongoing to study whether the synergistic inhibitory effect correlate not only with suppression of RI␣, but also with that of other relevant growth regulators such as growth factors and angiogenic factors. Taken together, these data suggest that selective down-regulation of PKAI, a key mitogenic signal transducer, is an important event able to markedly increase the antitumor efficacy of certain conventional cytotoxic drugs. As HYB 190 is a prototype of novel second generation oligodeoxynucleotides (the MBOs), which have shown an improved in vivo pharmacologic profile without toxicity (24) , our study provides a rationale for translating this combination treatment strategy into a clinical setting.
